The availability of weight-loss injections, under the brand names Ozempic, Wegovy, Saxenda, and Mounjaro, remains a topic of great interest throughout the autumn/winter of 2024. The genuine hype, characterized by sustained high demand and production bottlenecks, means many people are finding it difficult to obtain these medications. This is particularly concerning for individuals who rely on these drugs, such as for the treatment of obesity or type 2 diabetes, where guaranteed availability is crucial. However, there is hope for the supply of GLP-1 injections for weight loss. Various manufacturers are working intensively to improve the supply situation. Let’s take a closer look at the current situation and the outlook for the coming months.
Overweight, obesity, and diabetes in Germany: Current facts and figures
The number of people suffering from overweight and type 2 diabetes is continuously increasing in Germany and represents a growing health problem. This development is often fueled by unhealthy lifestyles, a lack of exercise, and poor dietary habits. Obesity in particular is closely linked to an increased risk of chronic diseases such as diabetes, cardiovascular disease, and certain types of cancer. Let’s look at the current statistics and facts to understand the scale of this problem.
Overweight and obesity in Germany
According to the latest study by the Robert Koch Institute (RKI), about 53% of adults in Germany are overweight (with a Body Mass Index of 25 or higher). Within this group, around 24% of adults are obese (with a BMI of 30 or higher). This means that nearly one in four adults in Germany is affected by obesity – a significant increase compared to previous decades.
The situation among children and adolescents is also cause for concern. According to current data, 15.4% of children and adolescents in Germany are overweight, and 5.9% are obese. These figures illustrate that being overweight and obese is a problem that starts at a young age and often persists into adulthood.
Diabetes in Germany
In parallel with the rise in overweight and obesity, the number of type 2 diabetes cases in Germany has also increased. It is estimated that over 8 million people currently live with diabetes in Germany, with the majority suffering from type 2 diabetes. This corresponds to about 10% of the adult population. It is particularly worrying that more and more young people are affected by type 2 diabetes, which was previously considered a condition of older age.
Overweight individuals have a significantly higher risk of developing diabetes because excess body fat negatively affects insulin sensitivity. This leads to impaired blood sugar regulation, which can eventually lead to diabetes.
Forecast for the coming years
Current trends suggest that the number of people with overweight, obesity, and diabetes will continue to rise in the coming years. It is expected that by the year 2030, about 30% of the German population could be obese if no effective countermeasures for weight loss are taken. The increase in type 2 diabetes is also expected to continue, as risk factors such as unhealthy diet, lack of exercise, and stress are widespread.
These alarming figures underscore the need for effective prevention and treatment strategies to curb the progression of these health crises. Weight-loss injections such as Saxenda, Ozempic, and Wegovy from the Danish pharmaceutical company Novo Nordisk, and Mounjaro with the active ingredient tirzepatide from the US pharmaceutical company Eli Lilly, can play an important role in this context, especially for people who have difficulty losing weight through diet and exercise alone.
Mounjaro weight-loss injection: An emerging medication with potential
A new prescription medication that shows great potential for weight reduction is Mounjaro. Since its introduction, demand in Germany has soared. Although it has been available in pharmacies since May 2024, there have repeatedly been shortages here as well. The good news is that manufacturers are planning to expand production in the near future, so the availability of Mounjaro should stabilize over the course of 2024. Therefore, those who have trouble purchasing Mounjaro can hope for improvement in the coming months.
Ozempic: What is the situation in Germany?
Ozempic, with the active ingredient semaglutide, one of the most frequently prescribed GLP-1 medications, is also in high demand, especially in lower dosages such as 0.25 mg and 0.5 mg. The availability of these dosages has been severely limited in recent months. The good news, however, is that manufacturers are planning to expand production capacities significantly by the beginning of 2025. This means that individuals wondering when Ozempic 0.25 mg will be back in stock can expect an improvement in the situation in the first quarter of 2025. In the meantime, it is recommended to check with pharmacies regularly and, if possible, switch to alternative preparations such as Saxenda or semaglutide tablets.
Semaglutide: Tablets for weight loss as an alternative to injections?
Instead of injections, semaglutide tablets can now be used in Germany for the treatment of type 2 diabetes. Since semaglutide tablets (Rybelsus) are becoming increasingly popular due to their easier administration, they could play a greater role for patients with obesity in the future. It is important to note, however, that treatment with semaglutide in Germany remains available by prescription only – both in tablet form and as an injection.
Wegovy for obesity: Shortages and future availability
Another popular weight-loss medication is the weight-loss injection Wegovy, which is also based on semaglutide.
Since mid-July 2023, doctors in Germany have also been able to prescribe the pre-filled pen from the manufacturer Novo Nordisk to patients with obesity.
Unfortunately, availability is currently severely limited here as well, as production capacities have not yet been able to keep up with rising demand. However, the forecast for 2025 is promising: it is expected that supply chains will stabilize by next year, making Wegovy more readily available for people with obesity in Germany.
Ozempic and Wegovy – Detailed differences
Ozempic and Wegovy, both developed by the manufacturer Novo Nordisk, have the same active ingredient: semaglutide. But although both medications aim to regulate blood sugar and aid weight loss, there are important differences. Ozempic was originally approved for the treatment of type 2 diabetes and is frequently prescribed for patients who suffer from obesity in addition to diabetes.
Wegovy, on the other hand, is explicitly approved for the treatment of severe obesity and contains a higher dose of semaglutide, which specifically suppresses appetite and slows gastric emptying – two critical factors in losing and maintaining weight.
Another difference lies in cost coverage: While Ozempic is covered by some statutory health insurance providers as part of diabetes treatment, patients often have to bear the costs for Wegovy themselves, despite a doctor’s prescription, which can amount to around 300 to 400 euros per month.
A phenomenon that occurs in connection with the use of both medications is the so-called “ozempic face,” where the face appears sunken due to rapid weight loss. Despite various potential side effects, many users experience significant support in losing weight and successfully maintain the weight lost. Nevertheless, the question remains as to how statutory cost coverage will develop in the future, as health insurance providers currently rarely cover the costs for Wegovy.
Saxenda: Stable, but with potential shortages
Saxenda, with the active ingredient liraglutide, is one of the few GLP-1 medications that is currently still relatively well available. Despite stable production, however, delivery delays can occur here as well if demand continues to rise. Individuals who rely on Saxenda should fill their prescriptions early to avoid potential supply shortages. Manufacturers are working to keep production consistently high, but here too: timely planning is crucial.
When will there be enough weight-loss medication? Outlook for the coming months
For everyone asking where the medication Ozempic is currently available or when the shortages will end, there is a positive outlook. Manufacturers are working at full speed to improve the availability of in-demand medications such as Ozempic, Wegovy, and Mounjaro.
The hope that the market launch of Wegovy would mean Ozempic is no longer used as an obesity medication and would be increasingly available for diabetes patients has unfortunately not come to pass. While the availability of Ozempic has since improved, supply shortages persist, and for Wegovy, demand remains higher than production.
The supply situation is expected to stabilize at the beginning of 2025. In the meantime, it is advisable to plan in close consultation with doctors and pharmacists to secure your own supplies and, if necessary, to switch to alternatives.
SoLean: Your reliable solution for weight-loss injections
At SOLean, we understand how important a stable supply of weight-loss injections is for our customers. That is why we are proud to be able to reliably offer Saxenda, Mounjaro, and Wegovy even in these difficult times. Thanks to our partnerships with pharmacies, we are able to ensure constant availability of these medications. In addition, we offer comprehensive consultation to ensure that you receive the best possible treatment that meets your individual needs.
Advantages at SoLean:
- Stable availability of Saxenda, Mounjaro, and Wegovy
- Fast and reliable shipping directly to your home
- Personal advice and support from our experienced team
If you are looking for a trustworthy source for weight-loss injections, SOLean is the right choice for you. We make sure that you receive your medication on time and accompany you on your path to a healthier life.
Conclusion: Weight-loss injection promises weight loss - High demand for weight management
Hype around weight-loss injections - one year of Wegovy in Germany.
In summary, the availability of weight-loss injections in Germany remains limited despite high interest.
Although these medications offer promising support for weight loss, they are not available over-the-counter, and patients must often bear the costs themselves, as they are rarely covered by statutory health insurance, making them unaffordable for many. Those who do gain access often benefit from improved weight control but must accept potential side effects, such as pancreatitis. The market is continuing to evolve, but it remains to be seen whether availability and cost coverage will improve in the future. Whether health insurance providers will contribute more in the future or whether alternative weight-loss injections will enter the market remains uncertain.
Sources:
